BC Cancer, part of the Provincial Health Services Authority

Published purpose

This project builds on the success of the work done over the last two years in establishing clinical grade manufacturing for both lentivirus and cell products, and in executing the first clinical trial using a made-in-Canada CD19 CAR T-cell therapy. The goal over the next 18 months is to build much-needed capacity in point-of-care (POC) manufacturing to support the clinical roll-out of novel CAR T-cell products and other personalized cell therapy products with the addition of three new POC manufacturing and clinical sites across Canada. In parallel, and with direct involvement of the NRC, it will be aimed to initiate a minimum of two new, high-content, academically motivated clinical trials to be started by the end of the project and completed with the next five years for the benefit of cancer patients from across Canada.